Sirna therapeutics targeting lpa

1. Sirna therapeutics targeting lpa decreases low-density lipoprotein cholesterol in humans (−19.70% (95% CI −26.22 to −13.19)).

   “and LDL-C by −19.70% [95% CI −26.22 to −13.19]”

   Reviewbetween weeks 34 and 36

   LPA -Targeted siRNAs Lower Lp(a) by Over 90%: A Meta-Analysis of Olpasiran, Lepodisiran, and Zerlasiran

   AHA Scientific Sessions 2025 abstract·Nov 3, 2025

More on Low-density lipoprotein cholesterol

1. Sirna therapeutics targeting lpa decreases Apolipoprotein B in humans (−15.95% (95% CI −19.36 to −12.54)).

   “siRNA therapies decreased ApoB by −15.95% [95% CI −19.36 to −12.54]”

   Reviewbetween weeks 34 and 36

   LPA -Targeted siRNAs Lower Lp(a) by Over 90%: A Meta-Analysis of Olpasiran, Lepodisiran, and Zerlasiran

   AHA Scientific Sessions 2025 abstract·Nov 3, 2025

More on Apolipoprotein B

1. Sirna therapeutics targeting lpa decreases lipoprotein in humans (−94.46% (95% CI −102.92 to −86.01)).

   “siRNA therapy achieved a significant pooled mean reduction in Lp(a) of −94.46% [95% CI −102.92 to −86.01]”

   Reviewbetween weeks 34 and 36

   LPA -Targeted siRNAs Lower Lp(a) by Over 90%: A Meta-Analysis of Olpasiran, Lepodisiran, and Zerlasiran

   AHA Scientific Sessions 2025 abstract·Nov 3, 2025

More on Lipoprotein